Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease

Ann Neurol. 2021 Sep;90(3):331-333. doi: 10.1002/ana.26167. Epub 2021 Aug 10.

Authors

Nuriel Moghavem¹, Victor W Henderson², Michael D Greicius³

Affiliations

¹ Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
² Departments of Epidemiology & Population Health and of Neurology & Neurological Sciences, Stanford University, Stanford, CA.
³ Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA.

PMID: 34278596
DOI: 10.1002/ana.26167

No abstract available

Publication types

Editorial

MeSH terms

Alzheimer Disease / drug therapy
Alzheimer Disease / economics*
Alzheimer Disease / epidemiology
Antibodies, Monoclonal, Humanized / economics*
Antibodies, Monoclonal, Humanized / therapeutic use
Clinical Trials, Phase III as Topic / methods
Humans
Insurance Coverage / economics*
Medicare / economics*
Treatment Outcome
United States / epidemiology

Substances

Antibodies, Monoclonal, Humanized
aducanumab

Grants and funding